Sharemaestro Newsreel

Truist Securities Adjusts IRhythm Technologies PT to $168 From $160, Maintains Buy Rating

Truist Securities has increased its price target for iRhythm Technologies (IRTC) to $168 from $160, while reiterating a Buy rating on the stock. This adjustment suggests a positive outlook on the company's future performance by the investment bank.

ETFs Investing in Insulet Corporation Stocks

This article lists various ETFs that hold Insulet Corporation (GOV) stocks, providing detailed information such as market value, weight, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return. The ETFs cover a range of investment styles …

Profound Medical (NASDAQ:PROF) Announces Earnings Results

Profound Medical (NASDAQ:PROF) exceeded quarterly earnings expectations, reporting an EPS of $0.26 against a projected loss of $0.22, with Q2 revenue rising 12% year-over-year. Despite some operational challenges like delayed shipments and uneven utilization, the company maintained its 2026 revenue target of $25 million …

Quanterix Corp (QTRX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Quanterix Corp (QTRX), detailing its current earnings forecast score, average price target, and analyst ratings. Based on 3 analysts, the stock has a "Hold" rating with an average price target of $6.50, suggesting a potential upside of …

Neuropace Inc (NPCE) Stock News Today

This page from TradingKey provides current stock information for Neuropace Inc (NPCE), including its stock price, market cap, and links to financial data, forecasts, and ownership details. As of the latest update, the stock was trading at $14.830, up 6.69%, with a market cap …

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2026: Revenue $39.01M, EPS ($0.14) — 10-Q Summary

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) reported its current quarter 2026 results, showing largely flat revenue year-over-year at $39.01M and a net loss that widened to ($44.74M), though diluted EPS remained ($0.14). The company is focusing on shifting towards clinical and commercial accounts, increasing …

UBS Adjusts Price Target on STERIS to $270 From $275, Maintains Buy Rating

UBS has adjusted its price target for STERIS (NYSE: STE) to $270, down from $275, while reaffirming a Buy rating on the stock. This revision comes as analysts reassess the company's valuation. Despite the slight reduction in the price target, UBS continues to recommend …

PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP

SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) that a securities class action has been filed after repeated surprise unit handpiece sales underperformance and gradual revelations of excess customer inventory levels …

Tandem Diabetes Care, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TNDM) 2026-08-07

Outset Medical, Inc. Q2 2026: Revenue $31.6M, EPS $(0.97) — 10-Q Summary

Outset Medical, Inc. reported its Q2 2026 results, showing essentially flat revenue year-over-year at $31.6M and an improved net loss of $18M, with diluted EPS at $(0.97). The company is focusing on accelerating acute care adoption and expanding into new markets, while gross margin …

Outset Medical Reports Second Quarter 2026 Results

Outset Medical, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting net revenue of $31.6 million, a 1% increase year-over-year, and a gross margin expansion to 42%. The company highlighted a three-year, $40 million agreement with HCA Healthcare and …

PAVmed Inc (PAVM) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for PAVmed Inc (PAVM), indicating a current earnings forecast score of 8.00 and an average price target of $12.00. Based on two analyst ratings, the stock is predominantly seen as a "Buy." The report also includes expected revenue …

Lifeward to issue Q2 results before 9:30 a.m. Aug. 14; no call

Lifeward (Nasdaq: LFWD) announced it will report its second-quarter 2026 financial results on Friday, August 14, 2026. A press release and quarterly report will be available and filed with the SEC before 9:30 a.m. ET. The company also stated it will not hold a …

TELA Bio Inc (TELA) Stock News Today

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

InspireMD, Inc. announced that its Compensation Committee approved inducement grants totaling 221,666 shares of restricted stock to a new non-executive employee. These grants were made outside of the company's 2021 Equity Incentive Plan but under its 2024 Inducement Plan, in accordance with Nasdaq Listing …

Tandem Diabetes Care Q2 Earnings Call Highlights

Dodge & Cox (NASDAQ: GEHC) discloses 47.3M-share, 10.5% holding in GE HealthCare

Dodge & Cox has filed an amended Schedule 13G, disclosing a beneficial ownership of 47,334,058 shares, representing a 10.5% stake in GE HealthCare Technologies Inc. The firm holds sole voting power over 44,872,703 shares and sole dispositive power over all 47,334,058 shares. Additionally, the …

Dodge & Cox (NASDAQ: GEHC) reports 8.3% stake in GE Healthcare common stock

Dodge & Cox, a California-based investment manager, has reported a beneficial ownership of 37,864,164 shares of GE Healthcare Technologies Inc. common stock, which represents 8.3% of the class. The firm holds sole voting power over 35,801,954 shares and sole dispositive power over all its …

NANO-X DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Nano-X Imaging Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – NNOX

NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nano-X Imaging Ltd. (NASDAQ: NNOX) between March 31, 2025 and April 17, 2026, inclusive (the “Class Period”), of the important August …

Can Weight-Loss Momentum Lift Hims & Hers Stock Before Q2 Earnings?

Hims & Hers Health, Inc. HIMS is scheduled to report second-quarter 2026 results on Aug. 10, after the closing bell. In the last reported quarter, the company's loss per share of 18 cents lagged the Zacks Consensus Estimate of earnings per share of 4 …

Why Bruker (BRKR) Is Down 20.3% After Q2 Impairment-Driven Loss And Soft 2026 Guidance

Intelligent Bio Solutions Inc (INBS) Stock News Today

This article provides current stock information for Intelligent Bio Solutions Inc (INBS), including its stock price, market capitalization, and a note that more news will be coming soon. It serves as a placeholder for financial news and analysis for the company. The current stock …

The SI-BONE, Inc. (NASDAQ:SIBN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

SI-BONE, Inc. reported second-quarter results showing revenues in line with analyst predictions and smaller-than-expected statutory losses. Analysts have moderately uplifted their sentiment, improving loss per share forecasts for 2026, though the consensus price target of US$25.00 remains unchanged. The company is forecast to grow …

iRhythm Holdings, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:IRTC) 2026-08-07

Treace Medical Concepts Inc (TMCI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Down - What's Next?

Tandem Diabetes Care (NASDAQ:TNDM) shares gapped down but later rose by 13.8%. Analyst ratings are mixed, with a consensus "Hold" and an average price target of $28.77, though Mizuho lowered its target to $20. The company reported an adjusted loss of $0.31 per share, …

51,393 Shares in Abbott Laboratories $ABT Purchased by St. Louis Financial Planners Asset Management LLC

St. Louis Financial Planners Asset Management LLC recently acquired 51,393 shares of Abbott Laboratories (NYSE:ABT) worth approximately $4.9 million, making it their 10th-largest holding. Institutional investors now own 75.18% of the company, which holds a "Moderate Buy" consensus rating from analysts despite some recent …

Envoy Medical Inc (COCH) Earnings Forecast: Future EPS & Revenue Growth Estimates

Narrow-Moat Steris' Recurring Revenue and Margin Improvement Create Opportunistic Outlook

Steris, a narrow-moat company, is a leading provider of sterilization products and services in healthcare. Recent acquisitions have expanded its portfolio, positioning it as a "one-stop shop" for outpatient settings. The company's focus on recurring revenue and margin improvements suggests an opportunistic outlook, further …

Rxsight Inc (RXST) Stock News Today

Inogen, Inc. (INGN) Stock Price, News, Quote & History

This Yahoo Finance page provides detailed financial information for Inogen, Inc. (INGN), a medical technology company specializing in respiratory health products. It includes real-time stock quotes, historical data, key financial metrics, performance overview, earnings trends, analyst insights, and comparison tools with similar companies in …

TriSalus Life Sciences Inc (TLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates

AxoGen Number of Employees 2026 | Employee Count & Headcount Data

AxoGen (NASDAQ: AXGN) has 652 employees globally as of March 2026, marking a 36.7% growth since 2023. The company is actively hiring with 57 job postings in 2026, and its workforce is primarily concentrated in North America. Despite growth, overall employee sentiment is negative …

QuidelOrtho (NASDAQ:QDEL) Shares Gap Down - Time to Sell?

QuidelOrtho (NASDAQ:QDEL) shares gapped down significantly, opening at $12.67 after closing at $16.32, and later trading near $11.98. The company reported better-than-expected quarterly earnings, with $0.13 EPS against a forecasted loss of $0.05 and revenue of $630.9 million. Despite this, analysts maintain a cautious …

HAEMONETICS CORP : BARRINGTON RESEARCH RAISES TARGET PRICE TO $95 FROM $89

Barrington Research has increased its target price for Haemonetics Corp (HAE.N) to $95 from $89. This adjustment reflects an updated valuation for the company. The article cites Reuters as the source of this information.

Earnings call transcript: Haemonetics beats Q1 2026 estimates, stock slips premarket

Haemonetics (HAE) reported stronger-than-expected fiscal first-quarter results, with adjusted EPS of $1.14 on revenue of $339 million, exceeding analyst estimates. Despite the beat and raised full-year revenue guidance, the stock declined 1.91% in premarket trading, indicating investor focus on the company's cautious outlook and …